The Australian Living Evidence Collaboration is aware of the preliminary results recently released from the REMAP-CAP trial, with implications for the treatment of patients with influenza in critical care.
In response, ALEC will be developing rapid, robust, evidence-based guidelines in consultation with relevant organisations, evidence specialists, people with lived experience and clinical experts.
The trial, known as the Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) uses an innovative trial design to determine and continuously update the optimal set of treatments for hospitalised patients with respiratory tract infections.
The team at the Australian Living Evidence Collaboration have seen the parallels between adaptive platform trials and living guidelines with our LATEST project. Integrating the two methodologies has the potential for a very smooth, rapid integration of good research into healthcare settings, where it’s needed most.
Our living guideline, focussed on drug treatments for people with severe influenza who are critically ill, will centre on priority questions. Experts, people with lived experience and relevant organisations will be an integral part of the process, quickly developing and disseminating a well-informed living guideline for those working in critical care.
ALEC’s track record for creating highly effective clinical practice guidelines was demonstrated in 2020 with the COVID-19 pandemic. Over the course of three years, our team produced over 170 recommendations, with daily searches and weekly updates that kept health professionals informed of evidence-based research and truly practical advice in a time of rampant misinformation. You can find out more about our work during COVID here.
The fast translation of critical research findings into practical guidance for health professionals is central to what we do, and due to continual technological advancements, more efficient than ever. We encourage you to check our Influenza page over the coming days and weeks for important evidence-based information pertaining to drug treatments for influenza in critical care.
Follow us on LinkedIn and X to ensure you don’t miss an update.
Contact us at [email protected] for questions regarding guideline development.
For questions regarding the REMAP-CAP trial, contact [email protected].